Re: Feasibility of the Use of Phosphodiesterase Type 5 Inhibitors in a Pharmacologic Prevention Program for Recurrent Priapism

Burnett AL; Bivalacqua TJ; Champion HC; Musicki B

doi:10.1016/j.eururo.2007.06.011

Re: Feasibility of the Use of Phosphodiesterase Type 5 Inhibitors in a Pharmacologic Prevention Program for Recurrent Priapism

Burnett AL, Bivalacqua TJ, Champion HC +1 more2006European UrologyLetter

10.1016/j.eururo.2007.06.011 PubMed

Summary

No abstract is available for this paper. It was published in European Urology in 2006 by Burnett AL and colleagues. Study type: Letter. The DOI and PubMed links above lead to the full record.

Part of CIRS Nexus · Curated by Lauren Lowenstein, The Biotoxin Lady